Our finding that HDAC inhibitors improve XLMTM pre-clinical phenotypes, along the known role of VPA in modulating DNA methylation [23, 44], led us to consider the role of the epigenome in XLMTM pathogenesis and VPA response. The gene discussed is HDAC9; the disease is X-linked myotubular myopathy.